Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong
Sponsor: The University of Hong Kong
Summary
This study evaluates the immunogenicity of adding inactivated influenza vaccine with southern hemisphere (SH) formulation to standard once-annual influenza vaccination with northern hemisphere (NH) formulation in older adults in Hong Kong over 9 years. Half of participants will receive twice-annual influenza vaccination with NH and SH formulation, while the other half will receive once-annual influenza vaccination with NH formulation and a placebo.
Official title: Immunogenicity of Twice-annual Vaccination Against Seasonal Influenza for Two Hemispheres in Older Adults in Hong Kong - a Randomised Controlled Trial
Key Details
Gender
All
Age Range
70 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2016-11-18
Completion Date
2026-09
Last Updated
2023-12-11
Healthy Volunteers
Yes
Conditions
Interventions
Inactivated influenza vaccine (NH formulation)
Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation
Inactivated influenza vaccine (SH formulation)
Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation
Placebo
Round 2 (May): 0.5mL normal saline
Locations (1)
The University of Hong Kong
Hong Kong, China